Figures & data
Table 1 Clinical Characteristics of Mild/Moderate COVID-19 Patients on Admission
Table 2 Clinical Features of Severe/Critical COVID-19 Patients
Table 3 Laboratory Finding and CT Imaging of Mild/Moderate COVID-19 Patients on Admission
Table 4 Laboratory Finding of Severe/Critical COVID-19 Patients
Table 5 Univariate and Multivariate COX Analysis of Progression of Mild/Moderate COVID-19
Table 6 Univariate and Multivariate COX Analysis of Survival of Severe/Critical COVID-19
Figure 2 Nomogram predicting 20-day, 40-day, 60-day, and 80-day progression probability of patients with non-severe COVID-19.
![Figure 2 Nomogram predicting 20-day, 40-day, 60-day, and 80-day progression probability of patients with non-severe COVID-19.](/cms/asset/9a63ad05-6228-4875-880a-ce25679a3bd6/dijg_a_12168280_f0002_b.jpg)
Figure 3 Kaplan–Meier curves of risk group stratification for non-progression to severe illness. (A) The cutoffs of neutrophils for each risk group were as follows: low risk: <6.3, and high risk: ≥6.3. (B) The cutoffs of lymphocytes for each risk group were as follows: low risk: ≥1.1, and high risk: <1.1. (C) The cutoffs of CK for each risk group were as follows: low risk: <200, and high risk: ≥200. (D) The cutoffs of LDH for each risk group were as follows: low risk: <250, and high risk: ≥250. (E) The cutoffs of CRP for each risk group were as follows: low risk: <4, and high risk: ≥4. (F) The cutoffs of total lesion volume ratio for each risk group were as follows: low risk: <10%, and high risk: ≥10%.
![Figure 3 Kaplan–Meier curves of risk group stratification for non-progression to severe illness. (A) The cutoffs of neutrophils for each risk group were as follows: low risk: <6.3, and high risk: ≥6.3. (B) The cutoffs of lymphocytes for each risk group were as follows: low risk: ≥1.1, and high risk: <1.1. (C) The cutoffs of CK for each risk group were as follows: low risk: <200, and high risk: ≥200. (D) The cutoffs of LDH for each risk group were as follows: low risk: <250, and high risk: ≥250. (E) The cutoffs of CRP for each risk group were as follows: low risk: <4, and high risk: ≥4. (F) The cutoffs of total lesion volume ratio for each risk group were as follows: low risk: <10%, and high risk: ≥10%.](/cms/asset/48530f0b-695a-4fdc-a0fc-dc900c2cfec5/dijg_a_12168280_f0003_c.jpg)
Figure 4 Risk score for progressor. Scores ranged from 0 to 6, with 0 indicating the lowest risk and 6 being the highest risk of progression. The numbers in the bar indicate the number of patients in the NP (red) and P (green) that were correctly predicted in the dataset.
![Figure 4 Risk score for progressor. Scores ranged from 0 to 6, with 0 indicating the lowest risk and 6 being the highest risk of progression. The numbers in the bar indicate the number of patients in the NP (red) and P (green) that were correctly predicted in the dataset.](/cms/asset/84d077e4-8392-4b33-8233-8ae18b6b9f95/dijg_a_12168280_f0004_c.jpg)
Figure 5 Nomogram predicting 20-day, 40-day, 60-day, and 80-day survival probability of patients with COVID-19.
![Figure 5 Nomogram predicting 20-day, 40-day, 60-day, and 80-day survival probability of patients with COVID-19.](/cms/asset/21980120-30dd-4c6c-b3c5-884511be34e8/dijg_a_12168280_f0005_b.jpg)
Figure 6 Kaplan–Meier curves of risk group stratification for survival probability. (A) Lymphocytes: low risk: ≥1.1, and high risk: <1.1. (B) BUN: low risk: <8.8, and high risk: ≥8.8. (C) CK-MB: low risk: <24, and high risk: ≥24. (D) LDH: low risk: <250, and high risk: ≥250. (E) PT: low risk: <15, and high risk: ≥15.
![Figure 6 Kaplan–Meier curves of risk group stratification for survival probability. (A) Lymphocytes: low risk: ≥1.1, and high risk: <1.1. (B) BUN: low risk: <8.8, and high risk: ≥8.8. (C) CK-MB: low risk: <24, and high risk: ≥24. (D) LDH: low risk: <250, and high risk: ≥250. (E) PT: low risk: <15, and high risk: ≥15.](/cms/asset/20f42670-8bb4-4187-8ebd-af992d7a7565/dijg_a_12168280_f0006_c.jpg)